Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This study found that digoxin treatment was significantly associated with anemia adverse reactions in patients with atrial fibrillation and heart failure, suggesting a need for caution in its clinical use.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This article discusses the importance of raising awareness about specific adverse drug reactions, methods of prevention, and the significance of reporting them to the FDA's MedWatch program, but reports no new clinical results.

This study found that minoxidil increased plasma renin activity in patients with hypertension through both an adrenergic mechanism related to heart rate changes and a secondary mechanism unrelated to propranolol.

This study optimized a screening assay to identify molecules that inhibit or enhance TRPM5 ion channel activity, which may have implications for treating dysfunctions linked to cardiac arrhythmias and diabetes.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This study found that arylhydantoin and arylthiohydantoin derivatives with hydroxybutyl or methyl side-chains showed superior androgen receptor binding affinity and may serve as promising radioiodinated AR ligands.

This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.

This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.

This study developed solid lipid nanoparticles for effective delivery of shRNA-encoding plasmids, showing reduced 5α-reductase levels in DU-145 cells without significant cytotoxicity.

This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.

This study demonstrated that the glycolytic inhibitor 2-deoxy-D-glucose enhances antiseizure effects by potentiating extrasynaptic tonic GABAergic inhibition through neurosteroidogenesis in hippocampal slices.

This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.

Gepant medications for migraines show varied safety profiles in this study, with specific adverse events reported across systems like gastrointestinal and skin disorders, highlighting the need for tailored treatment and monitoring.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

This study describes a planned multicenter randomized controlled trial to assess the safety, tolerability, and pharmacokinetics of subdermal gestrinone pellets in patients with deep infiltrative endometriosis-related pelvic pain, but it does not report any findings yet.

This study found that in a rat model, 14,15-EET may alleviate central poststroke pain by enhancing thalamic inhibition through neurosteroid signaling, potentially outperforming gabapentin in early-stage treatment.

In this study, the pharmacological action of dobutamine on rabbit retinae was found to be distinct from that of other dopamine analogs like apomorphine and N-methyl-dopamine.

This study found that the retinoid LGD1069 suppressed mammary tumorigenesis in a mouse model without observable toxicity, while TTNPB showed modest effects but was associated with significant toxicity.

This study observed no teratogenic effects of oral decongestants and surprisingly favorable neonatal outcomes in Swedish women who used them during pregnancy.

This case report describes a 20-year-old female who ingested an unknown quantity of minoxidil tablets in an overdose, presenting with cardiovascular symptoms, but her condition stabilized after supportive care.

This study found that hollow polydopamine nanoparticles enhanced the regenerative potency of the peptide RL-QN15, suggesting potential for improved therapeutic approaches in skin wound healing.

This study found that subcutaneous injections of guanethidine or 6-hydroxydopamine induced premature hair growth in mice, suggesting a role for sympathetic nerves in hair growth control.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This study reports that three synthesized PSMA-targeted radioimaging agents demonstrated high affinity and specific localization to prostate cancer tumors in a mouse model, highlighting their potential for cancer detection and monitoring.